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Abstract
Background: Colorectal cancer is the second most common tumor in developed countries, with a lifetime
prevalence of 5%. About one third of these tumors are located in the rectum. Surgery in terms of low anterior
resection with mesorectal excision is the central element in the treatment of rectal cancer being the only option
for definite cure. Creating a protective diverting stoma prevents complications like anastomotic failure and
meanwhile is the standard procedure. Bowel obstruction is one of the main and the clinically and economically
most relevant complication following closure of loop ileostomy. The best surgical technique for closure of loop
ileostomy has not been defined yet.
Methods/Design: A study protocol was developed on the basis of the only randomized controlled mono-center
trial to solve clinical equipoise concerning the optimal surgical technique for closure of loop ileostomy after low
anterior resection due to rectal cancer.
The HASTA trial is a multi-center pragmatic randomized controlled surgical trial with two parallel groups to compare
hand-suture versus stapling for closure of loop ileostomy. It will include 334 randomized patients undergoing closure of
loop ileostomy after low anterior resection with protective ileostomy due to rectal cancer in approximately 20 centers
consisting of German hospitals of all level of health care. The primary endpoint is the rate of bowel obstruction within
30 days after ileostomy closure. In addition, a set of surgical and general variables including quality of life will be
analyzed with a follow-up of 12 months. An investigators meeting with a practical session will help to minimize
performance bias and enforce protocol adherence. Centers are monitored centrally as well as on-site before and during
recruitment phase to assure inclusion, treatment and follow up according to the protocol.
Discussion: Aim of the HASTA trial is to evaluate the efficacy of hand-suture versus stapling for closure of loop
ileostomy in patients with rectal cancer.
Trial registration: German Clinical Trial Register Number: DRKS00000040
Background
Background and rationale
Colorectal cancer is the second most common tumor in
developed countries, with a lifetime prevalence of 5%
[1,2]. Approximately 30% of these tumors are located in
the rectum. Surgery forms the cornerstone in the
treatment of rectal cancer, with the low anterior resec-
tion (LAR) with totally mesorectal excision being the
standard procedure [3]. Today, a diverting protective
stoma should be used until definite healing of the ana-
stomosis is achieved [4,5]. So far, it remains still uncer-
tain whether a loop ileostomy or a colostomy is
preferable [6-8]. After a period of three months the ileo-
or colostomy is subsequently closed and intestinal conti-
nuity is re-established. Due to the high prevalence of
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in surgical practice.
Preliminary data
One randomized controlled trial (RCT) including 141
patients over 6 years has compared hand-sutured and
stapled anastomosis for closure of loop ileostomy so far
[9]. The results of this trial have shown a significantly
higher rate of postoperative bowel obstruction (14%
versus 3%, p = 0.0168) for patients who received hand-
sutured anastomosis. However, there are severe metho-
dological issues which impair the interpretation of this
trial. First, the trial included a heterogeneous group of
patients with many different underlying benign and
malignant diseases. Second, it was performed in a sin-
gle-center setting with only a low number of surgeons
performing the investigated techniques. Therefore, the
results reflect the situation of loop ileostomy closure at
this institution rather than practice in general. Third,
results of this trial are probably biased by learning curve
effects of participating surgeons [10]. The authors report
that two-thirds of bowel obstructions observed in the
trial occurred in the first half of the study. In addition,
all patients requiring re-operations had initial closure of
the loop ileostomy performed by senior registrars (as
opposed to consultant surgeons). Due to the methodolo-
gical and clinical limitations of this trial a multi-center
pragmatic trial is needed to confirm the observed
findings.
Objectives and hypotheses
The objective of the HASTA-Trial is to investigate
whether there is a difference in rate of bowel obstruction
one month after hand-suture as compared to stapling
loop ileostomy closure. If pHA/pHA denotes the rate of
occurrence of bowel obstruction within one month after
ileostomy closure in the hand-suture group (HA)/stapler
group (STA), then the following two-sided test problem
is assessed: H0:p HA =p STA vs. H1:p HA ≠ pSTA.
Methods/Design
Study population and Trial group
Patients with history of low anterior resection (LAR)
and creating of a protective loop ileostomy for rectal
cancer who are planned for elective closure of loop
ileostomy will be recruited for this trial.
T h eH A S T A - T r i a li sc o n d u c t e db yan a t i o n a ls t u d y
group consisting of certified bowel centers and other
German hospitals of all level of health care. Trial design
and management are under the responsibility of the
Study Center of the German Surgical Society, biostatisti-
cal planning, data management and analysis is per-
formed by the Institute of Medical Biometry and
Informatics, University of Heidelberg.
Subject inclusion criteria
￿ Patients equal or older than 18 years scheduled for
elective ileostomy closure after LAR
￿ Informed consent
Subject exclusion criteria
￿ Pathologic findings in routine preoperative diag-
nostic tests (e.g. anastomotic leakage) which do not
allow a safe ileostomy closure
￿ Participation in another intervention-trial with
interference of intervention and outcome of this
study
￿ Expected lack of compliance
Centers are asked to document potential patients in a
screening log. Thus, reasons for exclusion are
documented.
Sample size
The prior assumptions for sample size calculation are
based on the results of Hasegawa et al. (2000) ([9]) and
assume prevalence rates with respect to the primary
endpoint of 3% in the stapler group and 14% in the
hand-suture group. To detect this difference with the
two-sided chi-square test at a type I error rate of (two-
sided) with power, a sample size of n = 133 evaluable
patients (treatment and follow up according to the pro-
tocol) per group is necessary. It can be expected that
taking into account the covariate “skill of surgeon” in
the analysis will increase the power as compared to the
chi-square test. The drop out rate within one month
after index operation is expected to be about 20% over-
all. Therefore, another total of 68 patients have to be
randomized to obtain the required number of evaluable
patients. The total sample size to be randomized is
therefore 334 patients.
Randomization and blinding
The randomization numbers will be allocated to the two
groups in balanced permuted blocks and stratified by
center using the web-based software “Randomizer” pro-
vided by the Institute of Medical Informatics, Statistics
and Documentation of the Medical University of Graz
(http://www.randomizer.at). This software allows choos-
ing different randomization methods as well as different
sets of parameters for the chosen method.
To avoid any potential of predicting the group alloca-
tion of future patients, the block length is fixed in a
separate document that is withheld from the study site.
In addition, persons with the right to randomize with
the software described above do not have the right to
read or edit the randomization design chosen within the
software. The software stores the result of randomiza-
tion and patient characteristics as well as the name of
the person who randomized and the randomization date
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download this file. Patients are randomized the day
before or on the day the surgical intervention is
performed.
Patients are not blinded and blinding of the surgeon is
unfeasible. Typical symptoms for the primary outcome,
bowel obstruction, like productive vomiting, gastric tube
placement, severe constipation are detected during regular
patient care and documented in the medical record. Assess-
ment according to trial criteria is done by investigators.
Interventions
Treatment description
The following description of treatment is a recommen-
dation and should be followed by all participating sur-
geons. Technique for hand-suture can be modified
according to local standards. In contrast the stapling of
an anastomosis must be performed as stated below.
Standardized mobilization of loop ileostomy
The operation is initiated with an oval skin incision
around the ileostomy and temporarily closed by contin-
uous suture to prevent further stool contamination. The
loop ileostomy is then thoroughly mobilized from the
subcutaneous layer and from the abdominal wall until it
is loose and can be moved out of the peritoneal cavity.
Stapler group
The TLC-75-stapler (Ethicon, Norderstedt) is brought
into the two opened antimesenteric apexes of the intest-
inal shanks to facilitate side-to-side (functional end-to-
end) anastomosis (Figure 1). The apex of the loop and
the spout is cross-stapled with a refill of the TLC-stapler
followed by overstitching the cross-stapled line with a
Polydioxanon equivalent suture (USP 5-0/Ethicon,
Norderstedt). The intestine is then put back into the
peritoneal cavity. The abdominal wall is closed with
interrupted sutures using Polyglactin equivalent sutures
(USP 2). The subcutaneous tissue is not sutured and no
subcutaneous drainage is used. The skin can be closed
by either interrupted monofilament sutures or clips.
Hand-suture group
After thorough mobilisation the loop ileostomy is
resected using two bowel clamps. An end-to-end anasto-
mosis is performed as follows: a two-layer continuous
suture using four Polydioxanon equivalent sutures (USP
5-0). The inner layer consists of a transmural suture, the
outer layer of a sero-muscular suture. Alternatively,
interrupted sutures may be performed depending on
local standards. The abdominal wall and the skin are
closed in the same way as for stapled closure.
Permitted and not permitted medication(s)/treatment(s)
No other method of ileostomy than the randomized and
described technique in the protocol should be used for
anastomosis. Any protocol violation has to be reported
with a clear description.
The postoperative care is performed according to the
principles and standard of the department.
Outcomes (primary and secondary)
The primary endpoint is the occurrence of bowel
obstruction within 30 days after ileostomy closure.
Figure 1 Stapled side-to-side anastomosis before (a) and after (b) stapling.
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Bowel obstruction is defined as productive vomiting or the
need of gastric tube placement or absolute constipation
with a duration of at least three days. This definition is
based on the existing trial by Hasegawa [9] which provides
the data for sample size calculation of the HASTA-Trial.
Secondary endpoints are the time needed to perform
the procedure, wound infection, rate of re-operation due
to anastomotic leakage of the ileostomy closure, time to
first tolerance to solid food and first bowel movement,
whichever of these occurred last, length of postoperative
hospital stay, 30 days and 12 months mortality after
ileostomy closure, rate of re-operation and re-hospitali-
zation within one year due to bowel obstruction, costs
of surgical procedure for the institution (including
threads, stapler, time etc.), quality of life (EuroQol 5 D).
Three out of, five visits are documented by the investi-
gator in each center during in hospital phase (screening,
intervention and discharge), followed by two telephone
interviews for 30 days and 12 months follow up after
operation (Table 1 and Figure 2).
Data management and monitoring
Documentation
All protocol-required information collected during the
trial must be entered by the investigator, or designated
representative, in the case report form (CRF). A paper
based CRF is used to collect the data. The investigator,
or designated representative, should complete the CRF
pages as soon as possible after information is collected,
preferably on the same day that a trial subject is seen
for an examination, treatment, or any other trial proce-
dure. Any outstanding entries must be completed imme-
diately after the final examination. An explanation
should be given for all missing data.
The completed CRF must be reviewed and signed by
the investigator named in the trial protocol or by an
authorized sub-investigator. To ensure that the database
reproduces the CRF correctly, the Institute of Medical
Biometry and Informatics Heidelberg (IMBI) accom-
plishes a double entry of data. Completeness, validity
and plausibility of data are examined by validating pro-
grams, which thereby generate queries. The investigator
or the designated representatives are obliged to clarify
or explain the queries. At the end of the trial, the princi-
pal investigator will retain the originals of all CRF.
T h ed a t aw i l lb em a n a g e da n da n a l y z e di nt h ej o i n t
unit of SDGC and IMBI in accordance with the appro-
priate standard operating procedures (SOP).
Trial monitoring
Monitoring is carried out in accordance with ICH E6
(GCP) and standard operating procedures of the Coordi-
nating Centre for Clinical Studies (KKS) Heidelberg.
Two different monitoring strategies are used within as
the HASTA trial is part of the ADAMON project (Pro-
spective cluster-randomized study of trial-specific
adapted strategies for on-site monitoring in combination
with additional quality management measures [11]),
which is funded by the German Federal Ministry of
Education and Research (BMBF, 01 EZ 0876).
Risk-adapted monitoring strategy
Half of the trial centers, chosen at random, are monitored
by a risk-adapted monitoring strategy which is described in
a trial specific monitoring manual. Participating centers are
activated with an initiation visit by the monitor, who will
hand-out the prepared investigator site file. All relevant
trial issues are discussed and personnel are trained on trial
specific procedures, documentation and web-based rando-
mization. The monitor is in regular contact by phone or
e-mail with all participating centers to follow progression of
the study, protocol adherence, and to discuss trial related
problems. Further monitoring visits are carried out during
the course of the trial for source data verification of relevant
core data, i.e., patient informed consent, inclusion/exclusion
criteria, performed treatment, primary and secondary end-
points and serious adverse events. Frequency of regular
monitoring visits depends on the number of recruited
patients and the performance of each trial center. Every
trial center is visited at least once during the trial. Close-out
visits are not as a standard foreseen in the centers.
Full monitoring
The remaining participating centers will be monitored
by a “full” or 100% monitoring (control-intervention for
ADAMON) including: initiation visit, first regular moni-
toring visit (after inclusion of first patient), further regu-
lar monitoring visits (after inclusion of 8 additional
Table 1 Course of examinations
Visit 1
(=Screening)
2
(Operation)
3
(day of discharge)
4
(30 days post OP)
5
(12 ± 1 months post OP)
Demographics and baseline clinical data X
Eligibility criteria X
Randomization, Surgical intervention X
Clinical visit/Follow-up X X X
Quality of life (EuroQol 5 D) X X X
Safety X X X X
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recruited), 100% source data verification for all included
trial patients, close-out visit.
In addition, an efficient central supervision of the clin-
ical trial is established (central monitoring) for both
strategies. Investigators in the participating centers will
support the monitor in his/her activities.
Audits
A final audit is scheduled in the participating centers.
These audits are carried out to check whether the con-
duct of the study is in accordance with ICH-GCP regu-
lations. Independence from the trial personnel involved
in HASTA is guaranteed for every auditor. Investigators
have agreed to give auditors free access to all relevant
Population
Patients undergoing closure of protective loop ileostomy after low anterior 
resection
    
Screening 
day of 
admission 
Inclusion/Exclusion
Criteria
Not eligible
    
Eligible
    
Informed consent/ Enrollment
    
Day of 
operation
Preoperative randomization
    
    
Stapler group Hand-suture 
group
Day of 
discharge
Clinical visit: Outcomes 
30 days 
after 
surgery
Telephone interview:  
Outcomes
12 months 
after 
surgery
Telephone interview:  
Outcomes
Figure 2 Flowchart.
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monitoring strategies will be compared.
Assessment of safety
A c c o r d i n gt oI C H - G C Pt h et e r m“adverse event” covers
any clinically relevant sign, symptom, syndrome, illness
that appears or worsens in a subject during the period
of observation in the clinical trial and that may impair
the well-being of the subject.
Adverse events fall into the categories non-serious and
serious. Non-serious adverse events will not be docu-
mented in HASTA trial. The following conditions and
treatments are expected after the initial operation and
will therefore not be classified as AE: pain, nausea,
hyper-/hypotension, blood sugar problems, electrolyte
imbalances and other lab values out of normal range, if
they are not exceeding the duration and extent that can
be expected after such an operation.
However, all endpoint relevant complications (i.e.
bowel obstruction, wound infection, anastomotic leakage
of the ileostomy closure, re-operation) are explicitly
being asked for and documented in the CRF as endpoint
(not as adverse events). Any other complications that
are considered as clinically relevant by the investigator
should be documented in free text.
From the day the subject has signed informed consent
until the regular end of trial at 12 months follow-up or
until premature withdrawal of the patient, all serious
adverse events (SAE) must be documented on a “serious
adverse event form” available in the investigator site file.
Serious adverse events have to be reported by the
attending physician to the principal investigator within
5 days after the SAE becomes known.
It is the responsibility of the principal investigator to
register all SAEs and to check incoming SAEs as to
completeness, correctness and plausibility.
In case of any irregularities for example concerning
the frequency or type of SAE reported the principal
investigator will inform the members of the Independent
Data Safety Monitoring Board (DSMB) without delay. At
least once every 12 months, the DSMB will receive a
written safety report. The members of the DSMB then
report the result of the benefit/risk assessment to the
principal investigator and will give appropriate recom-
mendations concerning the continuation of the trial.
Analysis of safety related data is performed with
respect to frequency of SAE in both treatment groups
and frequency of SAE stratified by causality.
Statistical methods
Analysis
Analysis sets Each patient’s allocation to the different
analysis populations (full analysis set (FAS) according to
the intention-to-treat (ITT) principle, per protocol (PP)
analysis set, safety analysis set) will be defined prior to
the analysis. The allocation will be documented in the
statistical analysis plan. During the data review, devia-
tions from the protocol will be assessed as „minor” or
„major”. Major deviations from the protocol will lead to
the exclusion of a patient from the PP analysis set.
Confirmatory analysis The null-hypothesis is assessed
by testing the intervention effect in a logistic regression
model that takes into account the covariates “interven-
tion” (hand-suture/stapler) and “skill of surgeon” (board
certificate yes/no). Due to the high number of targeted
centers (approximately 20), the variable “center” for
which randomization was stratified is not planned to be
additionally included in the model. A two-sided type I
error rate of will be applied.
Confirmatory analysis will be primarily based on the
FAS which is consistent with the intention-to-treat
(ITT) principle by including all patients who were ran-
domized to the two groups. This approach reflects the
idea that the study should match as close as possible to
the conditions in clinical practice.
If a patient discontinues from the study prematurely,
missing data with respect to the primary outcome vari-
able will be replaced by ICA-r method described by Hig-
gins et al. (2008) [12].
Further analyses In addition to the evaluation of the
FAS, a PP analysis will be performed including all ran-
domized patients without major protocol violations.
The secondary variables will be analyzed descriptively
by tabulation of appropriate measures of the empirical
distributions, descriptive p-values for treatment group
comparisons and associated 95% confidence intervals.
Possible center effects will be analyzed, too. All addi-
tional evaluations will be described in the statistical
analysis plan, which will be fixed prior to database
closure.
Homogeneity of the treatment groups
The homogeneity of the treatment groups will be
described by comparison of the demographic data and
the baseline values.
Data management and analysis will be performed
using SAS, version 9.1 or higher.
Criteria for termination of the trial
The principal investigator has the right to terminate the
trial and to remove all trial material from the trial center
at any time in consultation with the trial statistician and
the steering committee. For any questions concerning
safety of trial subjects the DSMB should be consulted.
Reasons that may require trial termination include
potential health hazard caused by the study intervention
and indicated by the prevalence or severity of adverse
events, unsatisfactory patient enrollment with respect to
quality or quantity or data recording is severely inaccu-
rate or incomplete. Also, new external evidence may
necessitate termination of the trial.
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There are several institutions that ensure safety, trans-
parency and reproducibility of the trial. The steering
committee consists of eight independent members (sur-
geons, clinical investigators, biostatisticians). Tasks of
the steering committee are review of the trial protocol
before the beginning of the trial and evaluation of Data
Safety Monitoring Board (DSMB) recommendations
regarding premature study discontinuation. The DSMB
consists of three independent members (surgeons, bios-
tatistician). In case of any irregularities for example con-
cerning the frequency or type of SAE reported the
principal investigator will inform the members of the
independent DSMB without delay. At least once every
12 months, the DSMB will receive a written safety
report. The members of the DSMB then report the
result of the benefit/risk assessment to the principal
investigator and will give appropriate recommendations
concerning the continuation of the trial.
Investigator meeting and training
78% of centers participating in the HASTA trial are
non-university hospitals coming from the organization
of certified German bowel centers, some of them with
little trial experience. Therefore, we organized a 2-day
investigators meeting with following topics on the
agenda: introduction to the trial protocol and its
rationale, discussion of surgical procedures, preparation
for study initiation and patient documentation. All part-
ners from the trial management presented their respon-
sibilities: biometry, data management, monitoring,
project management and surgical coordination. To stan
dardize surgical procedures, an operative training ses-
sion was held in a special surgical laboratory. Partici-
pants were thus given the opportunity to practice
surgical techniques for stapling and hand-suture. 17 out
of 18 participants returned the SDGC questionnaire for
evaluation of content and rhetoric of the speech as well
as for the printed handout, giving a rating between 1.2
and 2.2 (1 is the best end and 6 is the worst end) to all
speakers. Yet, the operative session was unanimously
considered the highlight of the meeting. Participants
also commented very positively that ample time was
given for discussion and in question and answer ses-
sions. Thus the meeting was very well accepted by all
participants (see general evaluation table 2) and was
successful in forming a cooperative trial group.
Ethics
This study is accomplished according to the Helsinki
Declaration in its latest version dated 2004, the Medical
Association’s professional code of conduct and the inter-
national principles of the Good Clinical Practice (ICH-
GCP). The trial will also be carried out in compliance
Table 2 Evaluation of the investigators’ meeting
1 = exactly
applies (N)
2 = rather
applies (N)
2 = does rather not
apply (N)
3 = does not apply
at all (N)
Median
Communication of content was precise and
comprehensive
10 5 1.3
The meeting was well-arranged 14 2 1.1
Content was communicated on the meeting as
announced
12 3 1.1
There was a relation between theory and practice 10 6 1.3
The use of media was helpful for understanding 9 7 1.4
The schedule and duration was adequate 8 6 2 1.6
The learning success was supported by repetition
and summary
4 12 1.7
Questions were answered in an understandable
way
12 4 1.3
The meeting had a thread 10 6 1.4
The meeting augmented my state of knowledge 6 5 5 1.9
The meeting met my expectations 8 8 1.5
I agree with the study rationale 8 8 1.5
The study rationale is justified 9 6 1 1.5
The primary endpoint is plausible 8 8 1.5
I am able to perform the surgical procedures
according to the protocol
10 2 1 1 1.5
I was comfortable with the accommodation and
social program
10 6 1.4
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medical secrecy and the German Federal Data Protec-
tion Act will be observed. After termination the trial
will be reported in accordance with the CONSORT
statement [13].
Patients receive complete oral and written information
on the trial by a medical doctor and a written informed
consent has to be signed.
Before the start of the trial, the clinical trial protocol,
informed consent document, and any other appropriate
documents had been submitted to the independent
ethics committee (IEC). The documents were approved
by the independent ethics committee of the University
of Heidelberg Medical School on September 23, 2008.
Secondary approval is sought from all local ethics com-
mittees of the participating centers. The IEC must be
informed of all subsequent protocol amendments.
Amendments must be evaluated to determine whether
formal approval must be sought and whether the
informed consent document should also be revised. The
investigator must keep a record of all communications
with the IEC. The trial was registered by the German
Clinical Trial Register (http://www.germanctr.de/
index_de.html) with a unique identification number
(DRKS00000040) on October 27, 2008.
The trial management is committed to writing a scien-
tific publication in any case, even if the trial is stopped
early. The design of the trial and the trial results will be
published and the authorship will be assigned by the
trial management. Representatives of the four highest
recruiting trial centers will act as co-authors and each
participating center will be mentioned.
The first center was initiated in January 2009, the first
patient was randomized in February 2009. 334 patients
should be randomized within 20 months. After a follow-
up period of 12 months the trial should be terminated
in October 2011. Figure 3 shows the planned versus the
actual recruiting rate within the HASTA trial.
Discussion
If there are two or more treatment options for one clinical
condition a randomized, controlled trial with a clinically
relevant endpoint should determine which is more benefi-
cial to the patient [14]. Concerning closure of loop ileost-
omy after low anterior resection we are currently
observing a situation of clinical equipoise as there is only
one small, mono-center trial postulating that stapled ana-
stomosis is superior compared to hand-sewn anastomosis
regarding bowel obstruction. So we decided to design a
multicenter randomized, controlled trial with a sufficiently
powered sample size to answer this question. Volume of
documentation is restricted to essential and relevant vari-
ables and should result in high acceptance and little loss
of data. In special conditions requiring very complex
Figure 3 HASTA patient recruitment.
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dure and to choose specialized centers as participants of
the trial meaning an experimental design. As closure of
loop ileostomy is a common procedure performed by
community hospitals as well as by referral centers we
c h o s ea ni n d i v i d u a ld e s i g ni nt e r m so fap r a g m a t i ct r i a l .
The trial should reflect the reality in the treatment of this
condition. This is why the technique of performing the
hand-sewn anastomosis may be done according to local
standards. Learning a certain technique of hand anastomo-
sis results in a learning curve which impairs the results of
t h et r i a l[ 1 0 ]a n dw ed i dn o tw a n tt od i s p l a yl e a r n i n g
curves in this trial. The participants are free to perform
their routine treatment (i.e. use of drainage, abdominal
wall closure etc.) but their practice needs to be documen-
ted and will be reported. In contrast a stapled anastomosis
can be standardized easily across all centres. To minimize
performance bias the exact technique was taught to all
participants at the investigators meeting and opportunity
was given to practice in a wet lab. To avoid selection bias,
we have reduced inclusion and exclusion criteria to a strict
minimum. Participating centers have to maintain a screen-
ing log documenting all potential patients. Due to the nat-
ure of a pragmatic trial, special attention is given to
primary and secondary endpoints that are essential for the
assessment of both techniques. The primary endpoint
bowel obstruction is relevant from the patient perspective
as well as from a health care perspective. Bowel obstruc-
tion often requires prolonged hospitalization or re-
hospitalization of the patient. No general definition of the
term “bowel obstruction” is available neither does a con-
sensus statement exist. Therefore, it was defined according
to the prior trial to maintain comparability and allow
further pooling in a meta-analysis. In addition, the given
definition can be monitored easily from the source docu-
ment, i.e. the patient’s chart and thus observer bias can be
reduced.
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